Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Sequence up to 1,500 Tumor Samples for Cancer Research UK's ICGC Contribution

Premium

This story was originally published July 22.

Cancer Research UK has selected Illumina as a preferred service provider for whole-genome sequencing of cancer genomes as part of its contribution to the International Cancer Genome Consortium.

Illumina's sequencing services will first be applied toward prostate and esophageal cancers and will include whole-genome sequencing on the HiSeq 2000 of up to 1,500 samples over the next three years on both tumor and normal genomes.

In addition, Illumina will also provide expression and epigenetic services to characterize transcriptomic and epigenomic changes in the tumors.

Due to advances in sequencing technology, "we're now entering a 'golden era' for cancer research," Fiona Hemsley, head of strategic projects at Cancer Research UK, said in a statement.

Financial details of the agreement were not disclosed.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.